Germany's Alzchem Group Q1 EBITDA, sales rise on specialty chemicals focus

AlzChem AG

30/04/2026 06:03

Overview

Germany specialty chemicals firm's Q1 sales rose 3% yr/yr, EBITDA up 18%

Earnings growth driven by shift to specialty chemicals, especially Human Nutrition and Defense

Company confirms 2026 forecast for further sales and EBITDA growth

Outlook

Alzchem confirms 2026 forecast for further sales and EBITDA growth

Company expects growth to accelerate in the second half of 2026

Recommissioning of carbide furnace expected in July 2026

Result Drivers

PRODUCT MIX SHIFT - Co said improved earnings were mainly due to a shift toward specialty chemicals, especially in Human Nutrition and Defense

HUMAN NUTRITION AND DEFENSE DEMAND - Sustained high demand in Human Nutrition (Creapure, Creavitalis) and Defense (nitroguanidine) drove specialty chemicals sales growth

BASICS & INTERMEDIATES DECLINE - Sales in Basics & Intermediates fell due to weak steel industry demand and price pressure in agriculture and pharmaceuticals, but segment profitability improved slightly

Company press release: ID:nEQ9PvBlqa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EBITDA
EUR 32.30 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the specialty chemicals peer group is "buy."

Wall Street's median 12-month price target for Alzchem Group AG is €193.65, about 11.2% above its April 29 closing price of €174.10

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 24 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)